个人简介

刘立鸿于2015年获得中国科学院上海巴斯德研究所博士学位，随后在美国洛克菲勒大学艾滋病鸡尾酒疗法创始人何大一教授的课题组进行了博士后训练。自2021年至今，担任美国哥伦比亚大学助理教授。刘立鸿教授参与或主持了多项国内外重大科研项目，在新冠病毒和艾滋病研究领域取得了一系列具有国际影响力的科学突破，并拥有7项新冠病毒抗体和抗原诊断相关的国际专利。以第一作者或通讯作者，在Nature（6篇）、Cell、新英格兰医学杂志、柳叶刀、Immunity、Science Translational Medicine、Cell Host & Microbe等期刊上发表论文30余篇，谷歌学术总引用次数超过1万次。目前，其课题组专注于影响公共卫生的重大传染性疾病以及新发、突发传染病的研究。

教育经历

2001-09 至 2008-07, 新疆大学，本科与硕士

2010-09 至 2015-01, 中国科学院上海巴斯德研究所，博士

工作经历

2015-08 至 2019-12, 美国洛克菲勒大学，博士后

2020-01 至 2021-11, 美国哥伦比亚大学，副研究员

2021-12 至 2024-4, 美国哥伦比亚大学，助理教授

荣誉奖励

2022年获湖北省百人计划

社会服务

刘立鸿博士担任一系列杂志审稿专家，这些杂志包括：Cell Host & Microbe, Med, Cell Reports Medicine, iScience, The Journal of Infectious Diseases, The Lancet Regional Health, Journal of Medical Virology, AIDS, JAIDS, Frontier of Immunology, Scientific Reports, npj Vaccines, Virologica Sinica 等

科研领域

刘立鸿博士团队长期从事针对病毒感染和免疫应答的研究，着重在病原诊断、病毒和宿主相互作用、病毒免疫逃逸、抗体分离与药物筛选、疫苗设计和评估以及基因治疗等方向开展工作。

代表性论文

1. Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C, Gordon A, Liu L^*, Ho DD^*. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe. 2024 Mar 13;32(3):315-321.e3.

2. Wang Q, Guo Y, Liyuan Liu, Schwanz LT, Li Z, Nair MS, Ho J, Zhang RM, Iketani S, Yu J, Huang Y, Qu Y, Valdez R, Lauring AS, Huang Y, Gordon A, Wang HH, Liu L^*, Ho DD^*. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature. 2023 Dec;624(7992):639-644.

3. Wang Q, Bowen A, Ho J, Zhang RM, Valdez R, Stoneman E, Gordon A, Liu L^*, Ho DD^*. SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster. Lancet. 2023 Nov 18;402(10415):1827-1828.

4. Wang Q, Guo Y, Zhang RM, Ho J, Mohri H, Valdez R, Manthei DM, Gordon A, Liu L^*, Ho DD^*. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. The Lancet Infectious Diseases 2023 Oct;23(10):e397-e398. 

5. Wang Q, Guo Y, Tam AR, Valdez R, Gordon A, Liu L^*, Ho DD^*. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine. Cell Reports Medicine. 2023 Nov 21;4(11):101258. 

6. Liu L*^#, Casner RA^#, Guo Y^#, Wang Q^#, Iketani S^#, Chan JFW^#,Yu J, Dadonaite B, Nair MS, Mohri H, Reddem ER, Yuan S, Poon VK, Chan CC, Yuen KY, Sheng Z, Huang Y, Bloom JD, Shapiro L^*, Ho DD^*. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking. Immunity. 2023 Oct 10;56(10):2442-2455.e8.

7. Wang Q, Li Z, Guo Y, Mellis IA, Iketani S, Liu M, Yu J, Valdez R, Lauring AS, Sheng Z, Gordon A, Liu L^*, Ho DD^*. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2. iScience. 2023 Oct 18;26(11):108254. 

8. Wang Q, Yeh AY, Guo Y, Mohri H, Yu J, Ho DD^*, Liu L^*. Impaired potency of neutralizing antibodies against cell-cell fusion mediated by SARS-CoV-2. Emerg Microbes Infect. 2023 May 3:2210237. doi: 10.1080/22221751.2023.2210237. Epub ahead of print.

9. Wang Q, Iketani S, Li Z, Liu Liyuan, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A, Liu L^*, Ho DD^*. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023 doi.org/10.1016/j.cell.2022.12.018.

10. Wang Q, Bowen A, Tam AR, Valdez R, Stoneman E, Mellis IA, Gordon A, Liu L^*, Ho DD. SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster. Lancet Infect Dis. 2023 May;23(5):527-528.

11. Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L^*, Ho DD^*. Antibody Response to Omicron BA.4-BA.5 Bivalent Booster. N Engl J Med. 2023 Feb 9;388(6):567-569.

12. Wang Q, Li Z, Ho J, Guo Y, Yeh AY, Mohri H, Liu M, Wang M, Yu J, Shah JG, Chang JY, Herbas F, Yin MT, Sobieszczyk ME, Sheng Z, Liu L^*, Ho DD^*. Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation. Lancet Infect Dis. 2022 Oct 31:S1473-3099(22)00694-6.

13. Wang Q, Iketani S, Li Z, Guo Y, Yeh AY, Liu M, Yu J, Sheng Z, Huang Y, Liu L^*, Ho DD^*. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. Cell Host Microbe. 2022 Sep 6:S1931-3128(22)00419-X.

14. Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, Wang M, Yu J, Bowen AD, Chang JY, Shah JG, Nguyen N, Chen Z, Meyers K, Yin MT, Sobieszczyk ME, Sheng Z, Huang Y, Liu L^* & Ho DD^*. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5. Nature. 2022 Jul 5:1-3.

15. Liu L^#, Iketani S, Guo Y, Reddem ER, Casner RG, Nair MS, Yu J, Chan JF, Wang M, Cerutti G, Li Z, Morano NC, Castagna CD, Corredor L, Chu H, Yuan S, Poon VK, Chan CC, Chen Z, Luo Y, Cunningham M, Chavez A, Yin MT, Perlin DS, Tsuji M, Yuen KY, Kwong PD, Sheng Z, Huang Y, Shapiro L & Ho DD. An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Science Translational Medicine. 2022; 14(646):eabn6859.

16. Iketani S^#, Liu L^#, Guo Y^#, Liyuan Liu^#, Chan JF^#, Huang Y, Wang M, Luo Y, Yu J, Chu H, Chik KK, Yuen TT, Yin MT, Sobieszczyk ME, Huang Y, Yuen KY, Wang HH, Sheng Z & Ho DD. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 2022; 604(7906):553-6.

17. Liu L^#, Iketani S^#, Guo Y^#, Chan JF^#, Wang M^#, Liyuan Liu^#, Luo Y, Chu H, Huang Y, Nair MS, Yu J, Chik KK, Yuen TT, Yoon C, To KK, Chen H, Yin MT, Sobieszczyk ME, Huang Y, Wang HH, Sheng Z, Yuen KY & Ho DD. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 2022; 602(7898):676-81.

18. Cerutti G^#, Guo Y^#, Liu L^#, Liyuan Liu^#, Zhang Z, Luo Y, Huang Y, Wang HH, Ho DD, Sheng Z & Shapiro L. Cryo-EM structure of the SARS-CoV-2 Omicron spike. Cell Rep. 2022 Mar 1;38(9):110428.

19. Iketani S^#, Liu L^#, Nair MS^#, Chandrashekar A, Mohri H, Wang M, Barouch DH, Huang Y, and Ho DD. Ad26.COV2.S boosts humoral and cellular immune responses following BNT162b2 vaccination. Emerging Microbes & Infections 2021; 10(1):2220-2222.

20. Wang P^#, Nair MS^#, Liu L^#, Iketani S^#, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y, and Ho DD. Nature 2021; Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature 2021;593, 130-135.

21. Liu L^#, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L and Ho DD. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 2020; 584(7821): 450-456.

22. Wang P^#, Liu L^#, Nair MS^#, Yin MT^#, Luo Y, Wang Q, Yuan T, Mori K, Solis AG, Yamashita M, Purpura LJ, Laracy JC, Yu J, Sodroski J, Huang Y and Ho DD. SARS-CoV-2 Neutralizing Antibody Responses Are More Robust in Patients with Severe Disease. Emerging Microbes & Infections 2020;9(1):2091-2093. 

23. Wang Q^#, Liu L^#, Ren W, Gettie A, Wang H, Liang Q, Shi X, Montefiori DC, Zhou T and Zhang L. A Single Substitution in gp41 Modulates the Neutralization Profile of SHIV during In Vivo Adaptation. Cell Rep 2019; 27(9): 2593-2607.

24. Liu L^#, Wang W, Matz J, Ye C, Bracq L, Delon J, Kimata JT, Chen Z, Benichou S and Zhou P. The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1. J Virol 2016; 90(23): 10642-10659.

25. Liu L^#, Wen M, Zhu Q, Kimata JT and Zhou P. Glycosyl Phosphatidylinositol-Anchored C34 Peptide Derived From Human Immunodeficiency Virus Type 1 Gp41 Is a Potent Entry Inhibitor. J Neuroimmune Pharmacol 2016; 11(3): 601-10.

26. Liu L^#, Wang W, Yang L, Ren H, Kimata JT and Zhou P. Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor. J Virol 2013; 87(3): 1899-905.

27. Liu L^#, Wen M, Wang W, Wang S, Yang L, Liu Y, Qian M, Zhang L, Shao Y, Kimata JT and Zhou P. Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol- anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16. J Virol 2011; 85(17): 8467-76.

实验室简介

刘立鸿博士实验室专注于影响我国公共卫生健康安全的重大传染性疾病，以及新发、突发传染病的研究。其实验室着重的科研方向包括：1. 阐释重大传染病性病毒中和免疫逃逸的分子机制; 2.分离出针对重大传染病性病毒的中和抗体，并进行相应的体内实验; 3.开发针对重大传染病性病毒的广谱疫苗; 4. 验证新型膜结合抗体（GPI锚定的抗体）基因治疗手段在人源化老鼠及恒河猴体内的抗病毒活性。